MedTrace Logo

A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects

NCT01540864 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2015-09-04

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and effect of HPP404 versus placebo on body weight in overweight or obese subjects.

Conditions

Interventions

DRUG

HPP404

Administered orally once daily for 26 weeks

DRUG

Placebo

Administered orally once daily for 26 weeks

Sponsors & Collaborators

  • High Point Pharmaceuticals, LLC.

    lead INDUSTRY

Principal Investigators

  • Enrikas Vainorius, M.D. · High Point Pharmaceuticals, LLC.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01540864 on ClinicalTrials.gov